Rebecca S. Gelman, PhD
Associate Professor, Department of Medicine, Harvard Medical School
Associate Professor of Biostatistics, Biostatistics and Computational Biology, Dana-Farber Cancer Institute
DF/HCC Program AffiliationBreast CancerBiostatistics and Computational Biology
My oncology research is related to breast cancer, biostatistics, and immunology. The breast cancer research includes studies of long-term toxicity (e.g. cardiac events after doxorubicin and/or radiation to left chest, MDS after alkylating agents), a recent grant submission on mathematical models of the effects of current and new breast cancer imaging methodology and therapy changes on national survival statistics, and studies of prognostic factors, most recently in DCIS patients. The immunology research includes studies of immunogenetics in mice and studies of patient and assay technique factors which influence the variability of tests such as lymphoproliferative assays, cytotoxic T lymphocyte assays, and immunophenotyping. The biostatistics research is related to breast cancer (e.g., competing risks methodology, analysis of non-proportional hazards, computing methods for SAGE analysis) or to immunology (e.g., interval censoring in animal studies, robust estimates of coefficient of variation in lab studies).
View All Publications